dermatological conditions
Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
Almirall and Absci expand AI dermatological drug discovery partnership
The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target
Almirall hosts Skin Academy to advance skin science and dermatology treatments
The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases
Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis
The inflammatory skin condition occurs in approximately 7.3% of adults in the US
Almirall announces NICE recommendation for Ebglyss in atopic dermatitis
The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK
Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients
Nearly 77% of psoriasis patients report that the condition negatively affects their well-being
Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis
The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases
Almirall survey reveals limited knowledge of most common precancerous skin condition
An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions
UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis
Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches
Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis
The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide
Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m
ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa